BioCentury | Jun 25, 2009
Strategy

Science for export

...2008) 2000 Cologne, Germany $35.4M IonGate Biosciences GmbH Membrane measurement tools 2000 Frankfurt, Germany $8.2M Jado Technologies GmbH...
BioCentury | Sep 11, 2008
Targets & Mechanisms

Skin-deep Target

...understanding of the pathways involved and possible intervention strategies," said Charl van Zyl, CEO of Jado Technologies GmbH...
...take and would provide more thorough protection than the all-over application of a topical agent. Jado...
...Boston, Mass. Genentech Inc. (NYSE:DNA), South San Francisco, Calif. Harvard Medical School , Boston, Mass. Jado Technologies GmbH...
BioCentury | Jul 7, 2008
Clinical News

TF002: Phase II started

...double-blind, placebo-controlled, German Phase II trial of oral TF002 in 75 patients for 8 weeks. Jado Technologies GmbH...
BioCentury | May 5, 2008
Product Development

Ace of BACE

...inhibitory interactions in the BACE enzyme." Details of the optimization process have not been disclosed. Jado Technologies GmbH...
...London, U.K. CoMentis Inc. , South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K Jado Technologies GmbH...
BioCentury | May 1, 2008
Distillery Techniques

This Week in Techniques

...of Molecular Cell Biology and Genetics and by the Technical University of Dresden; licensed to JADO Technologies GmbH...
BioCentury | May 1, 2008
Cover Story

Cutting the Synaptic Cord

...founder of Jado Technologies GmbH , which is developing technology for targeting therapeutics to lipid rafts. 7 Jado...
...Jado . The Science report underscores the importance of lipid rafts in disease and validates Jado's...
...composition and dynamic nature. "We are a bit of a lone voice," said Zyl. Although Jado...
BioCentury | Feb 25, 2008
Clinical News

TF002: Phase IIa data

...reduced the number of mast cells and did not induce skin atrophy compared with hydrocortisone. Jado Technologies GmbH...
BioCentury | Sep 10, 2007
Company News

Jado management update

Jado Technologies GmbH , Dresden, Germany Business: Infectious, Neurology, Inflammation Hired: Charl van Zyl as CEO, formerly European head of marketing and sales at Novartis AG ; he replaces Gary Jennings, who will remain CSO WIR...
BioCentury | Apr 30, 2007
Clinical News

TF002: Phase II started

...Jado started a double-blind, placebo-controlled, German Phase II trial in 30 patients. Jado Technologies GmbH , Dresden, Germany...
BioCentury | Apr 30, 2007
Product Development

Sinking fatty rafts

...start of a Phase IIa trial of a reprofiled compound to treat cutaneous mastocytosis that Jado...
...distinct patterns of densely packed lipids in the cell membrane, such as sphingolipids and cholesterol. Jado...
...membrane exactly where the virus is budding, using a variety of imaging technologies," Jennings said. Jado...
Items per page:
1 - 10 of 10
BioCentury | Jun 25, 2009
Strategy

Science for export

...2008) 2000 Cologne, Germany $35.4M IonGate Biosciences GmbH Membrane measurement tools 2000 Frankfurt, Germany $8.2M Jado Technologies GmbH...
BioCentury | Sep 11, 2008
Targets & Mechanisms

Skin-deep Target

...understanding of the pathways involved and possible intervention strategies," said Charl van Zyl, CEO of Jado Technologies GmbH...
...take and would provide more thorough protection than the all-over application of a topical agent. Jado...
...Boston, Mass. Genentech Inc. (NYSE:DNA), South San Francisco, Calif. Harvard Medical School , Boston, Mass. Jado Technologies GmbH...
BioCentury | Jul 7, 2008
Clinical News

TF002: Phase II started

...double-blind, placebo-controlled, German Phase II trial of oral TF002 in 75 patients for 8 weeks. Jado Technologies GmbH...
BioCentury | May 5, 2008
Product Development

Ace of BACE

...inhibitory interactions in the BACE enzyme." Details of the optimization process have not been disclosed. Jado Technologies GmbH...
...London, U.K. CoMentis Inc. , South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K Jado Technologies GmbH...
BioCentury | May 1, 2008
Distillery Techniques

This Week in Techniques

...of Molecular Cell Biology and Genetics and by the Technical University of Dresden; licensed to JADO Technologies GmbH...
BioCentury | May 1, 2008
Cover Story

Cutting the Synaptic Cord

...founder of Jado Technologies GmbH , which is developing technology for targeting therapeutics to lipid rafts. 7 Jado...
...Jado . The Science report underscores the importance of lipid rafts in disease and validates Jado's...
...composition and dynamic nature. "We are a bit of a lone voice," said Zyl. Although Jado...
BioCentury | Feb 25, 2008
Clinical News

TF002: Phase IIa data

...reduced the number of mast cells and did not induce skin atrophy compared with hydrocortisone. Jado Technologies GmbH...
BioCentury | Sep 10, 2007
Company News

Jado management update

Jado Technologies GmbH , Dresden, Germany Business: Infectious, Neurology, Inflammation Hired: Charl van Zyl as CEO, formerly European head of marketing and sales at Novartis AG ; he replaces Gary Jennings, who will remain CSO WIR...
BioCentury | Apr 30, 2007
Clinical News

TF002: Phase II started

...Jado started a double-blind, placebo-controlled, German Phase II trial in 30 patients. Jado Technologies GmbH , Dresden, Germany...
BioCentury | Apr 30, 2007
Product Development

Sinking fatty rafts

...start of a Phase IIa trial of a reprofiled compound to treat cutaneous mastocytosis that Jado...
...distinct patterns of densely packed lipids in the cell membrane, such as sphingolipids and cholesterol. Jado...
...membrane exactly where the virus is budding, using a variety of imaging technologies," Jennings said. Jado...
Items per page:
1 - 10 of 10